Oncology

Fission yeast is a low cost and fast system that can improve the cancer drug discovery process.

Top news of the day from across the health care landscape.

A method to detect underwater structure damage could be used to detect breast cancer.

A drug used to treat kidney cancer could be effective fighting several types of the disease.

Only 58% of breast cancer survivors received follow-up mammograms in 2007.

Top news of the week in oncology and cancer drug development.

Researchers found a low-cost approach to examine individual cancer cells, which could lead to a breakthrough in treatments.

Debiopharm International joins the Merck-Pfizer alliance for non-small cell lung cancer treatment research.

A nonsteroid anti-inflammatory drug used to treat common colds blocks bladder cancer cells from spreading in mice.

Positive results in the KEYNOTE-045 clinical trial of Keytruda showed improved overall survival.

The widely publicized untested oncology drug scandal could lead to better clinical practice.

Catalent Pharma Solutions and Moderna Therapeutics supports manufacturing of cancer vaccines.

Tennessee pharmacist admits to falsifying prior authorizations, medical lab reports, and drug test results for at least 51 hepatitis C patients prescribed Sovaldi, Harvoni, Viekira Pak, and Daklinza.

Pharmacists should keep tabs on the mental state of patients treated for lung cancer.

First-line pembrolizumab in addition to standard chemotherapy improved response rates and survival in patients with advanced non-small cell lung cancer.

Androgen deprivation therapy may increase the risk of developing dementia.

High-risk soft tissue sarcoma patients given anthracycline plus ifosfamide were found to have significant increases in survival.

Top news of the day from across the health care landscape.

Superior progression-free survival achieved with cabozantinib over sunitinib in patients with metastatic renal cell carcinoma.

An injection of flufenamic acid prevented invasive cancer cell activities in mouse models.

Supplements given to prostate cancer patients following radiotherapy could harm disease outcomes.

Study challenges previous findings that suggest night shift work increases the risk of breast cancer.

Immunotherapy showed promise in first- and second-line therapy for patients with metastatic bladder cancer.

Survey findings show a high level of integration of palliative care in advanced cancer patients.

Top news of the day from across the health care landscape.

Xtandi’s revised label will include results a study showing improve progression-free survival in prostate cancer.

Experimental treatment uses mRNA expression from tumors to identify responders.

No change in prostate-specific antigen tests for cancer was found before and after new screening guidelines.